Innovation

Only specialized statisticians discussed indirect comparisons in the past but over the years the topic developed into something, every statistician should know about.

In this episode, Benjamin and I talk about the important reasons for using indirect comparison (IC). We specifically address the following points:

During this episode, we review some highlights from this year. It’ll help you remember a couple of lessons learned or inspire you to listen to some episodes (again).

We talk about:

Interview with Trevor Smart

What’s interesting about the early phase?
What are the typical decisions for phase II?
Speaking about a new indication, how are decisions being taken across the industry?
How should we think about phase II studies in this setting?
What statistical approaches do we have to formulate this thinking?

In this episode, Trevor and I discuss a case study to go through the step by step procedure of phase II. We also talk about the following points:

Do you want to have fun at work?
Do you want to experience satisfaction?
Do you want to get things done at work?

Getting into flow is about these things. Today, we will speak about a research on how to get into the flow and reach your peak performance.

This is awesome for everybody, most especially, for brain workers like us.
In this episode, we talk about the following points:

Interview with Georgia Salanti

Do you know why network meta-analyses (NMA) important?
Do you wonder what steps are included in NMAs?

Network meta-analysis is a very important field, especially for multiple treatment options where a direct comparison is impossible without using this systematic review and analysis.

In today’s episode, I discuss with Georgia the following:

Interview with Richard Zink

What bigger trends do we see in the biopharmaceutical industry, which will have an impact for statisticians?
. . . in terms of technology changes?
. . . in terms of regulatory changes?
. . . in terms of political/society changes?
What can statisticians do to prepare for these changes?

In this discussion with the current ASA biopharm chair – Richard Zink – we’re covering a wide range of topics: